There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immutep Limited (Other OTC:IMMP), VistaGen Therapeutics (NASDAQ:VTGN) and Pfizer (NYSE:PFE) with bullish sentiments.
Immutep Limited (IMMP)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep Limited today and set a price target of $7. The company’s shares closed yesterday at $2.92.
McCarthy wrote:
“Immutep provided a corporate update and expected data milestones ahead for the remainder of 2018 and into 2019. The company also has ~$17M (USD) in cash which should be sufficient runway at the current burn rate of ~$14M per year to reach into late 2019.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 3.5% and a 39.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Immutep Limited has an analyst consensus of Moderate Buy, with a price target consensus of $7.
See today’s analyst top recommended stocks >>
VistaGen Therapeutics (VTGN)
Maxim Group analyst Caroline Palomeque maintained a Buy rating on VistaGen Therapeutics today and set a price target of $6. The company’s shares closed yesterday at $2.03.
Palomeque commented:
“VistaGen reported F2Q19 (Sep) with a net loss of ($7.7M) and ended the period with $7.8M in cash, excluding $2.4M from a combination of private placement and warrant exercises. With just over $10M in cash, the company should have runway into mid-2019 and through the next inflection point; P2 ELEVATE data read out of AV-101 in major depressive disorder (MDD), expected in 2Q19.”
According to TipRanks.com, Palomeque ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.2% and a 26.6% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, Anavex Life Sciences, and Daré Bioscience Inc.
Currently, the analyst consensus on VistaGen Therapeutics is a Strong Buy with an average price target of $11.33.
Pfizer (PFE)
In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Pfizer, with a price target of $53. The company’s shares closed yesterday at $43.23.
Chen observed:
“We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.1% and a 38.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $44.45, which is a 2.8% upside from current levels. In a report issued on October 24, BMO Capital also maintained a Buy rating on the stock with a $47 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
